Annual report pursuant to Section 13 and 15(d)

Segments (Tables)

v3.23.1
Segments (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of business segments primarily based on revenues and net
    For the years ended
December 31,
 
    2022      2021  
Revenues            
Therapeutics   $
-
    $
-
 
Clinics     486,559       15,062  
Total revenues     486,559       15,062  
                 
Net loss                
Drug Research and Development     (11,727,885 )     (1,908,925 )
Clinics     (2,208,567 )     (264,596 )
Total net loss   $ (13,936,452 )   $ (2,173,521 )